Shrinidhi Nathany/LinkedIn
Dec 16, 2025, 23:14
Shrinidhi Nathany: MRD in AML – From a Test to a Treatment Decision
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, posted on LinkedIn:
“MRD in AML: From a Test to a Treatment Decision (ELN-DAVID 2025 Update)
Measurable residual disease (MRD) has firmly moved beyond being a laboratory metric.
The 2025 ELN-DAVID consensus update positions MRD as a central clinical decision-making tool in acute myeloid leukemia.
What’s new and practice-changing?
- MRD interpretation is now genetics-specific, aligned with ELN 2022 risk groups
- Introduction of low-level MRD (MRD-LL) and qualitative MRD response categories – Optimal, Warning, High-risk
- Clear linkage of MRD results to clinical action, not just prognosis
- Ultra-high-sensitivity NGS (≤0.01%) now recommended for FLT3-ITD MRD, especially pre-transplant
- Refined, lower thresholds for NPM1 MRD, with clear PB vs BM distinctions
- Explicit caution against misinterpreting CHIP-associated mutations as MRD
Why this matters
- MRD is no longer binary. The same MRD level can mean very different things depending on:
genetics, assay, tissue, and timing. - This framework finally brings context and clarity to MRD-guided decisions.
For clinicians, pathologists, and transplant teams, this update is a must-read and should rapidly translate into:
standardized reporting, multidisciplinary discussion, and more precise patient care.”
Stay informed with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience